The World of Immunization: Achievements, Challenges, and Strategic Vision for the Next Decade
Open accessThe DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Abstract
Immunization is among the most cost-effective public health interventions available and is estimated to have averted at least 37 million deaths between 2000 and 2019. Since the establishment of the Expanded Programme on Immunization in 1974, global vaccination coverage increased and the coverage gap between rich and poor countries decreased. Creation of Gavi, the Vaccine Alliance, in 2000 allowed the poorest countries in the world to benefit from new, life-saving vaccines and expand the breadth of protection against an increasing number of vaccine-preventable diseases. Despite this progress, inequities in access to and uptake of vaccines persist. Opportunities to realize the full potential of vaccines are within reach but require focused, tailored and committed action by Governments and immunization stakeholders. The Immunization Agenda 2030 provides a framework for action during the next decade to attain a world where everyone, everywhere, at every age fully benefits from vaccines for good health and well-being.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures







Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz
(2013) · Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz · doi:10.1007/103.1437-1588 · Cited by 11,796
de Figueiredo, A., Simas, C., Karafillakis, E., Paterson, P., & Larson, H. J. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31558-0 · Cited by 1,143 · cited 1×
“A recent review found that while confidence in vaccines fell in some countries, it improved in others, highlighting the need for continuous monitoring and corrective actions [70].”
Background(2013) · Vaccine · doi:10.1016/j.vaccine.2013.02.015 · Cited by 551
Lane, S., MacDonald, N. E., Marti, M., & Dumolard, L. (2018) · Vaccine · doi:10.1016/j.vaccine.2018.03.063 · Cited by 530 · cited 2×
“There were varied reasons cited for hesitancy with heterogeneity across countries [68].”
BackgroundMethodReturn On Investment From Childhood Immunization In Low- And Middle-Income Countries, 2011–20
Ozawa, S., Clark, S., Portnoy, A., Grewal, S., Brenzel, L., & Walker, D. G. (2016) · Health Affairs · doi:10.1377/hlthaff.2015.1086 · Cited by 371
Progress Toward Regional Measles Elimination — Worldwide, 2000–2019
Patel, M. K., Goodson, J. L., Alexander, J. P., Kretsinger, K., Sodha, S. V., Steulet, C., Gacic-Dobo, M., Rota, P. A., McFarland, J., Menning, L., et al. (2020) · MMWR. Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm6945a6 · Cited by 349 · cited 2×
“Over 19 million children did not receive measles vaccination in 2019 [21].”
BackgroundTurner, N. (2009) · PubMed · Cited by 306
Li, X., Mukandavire, C., Cucunubá, Z. M., Echeverria Londono, S., Abbas, K., Clapham, H. E., Jit, M., Johnson, H. L., Papadopoulos, T., Vynnycky, E., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(20)32657-x · Cited by 300 · cited 1×
“It is estimated that vaccination has averted at least 37 million deaths (95% credible interval 30–48) between 2000 and 2019, representing a 45% decline in deaths due to 10 vaccine-preventable diseases (Haemophilus influenzae type b [Hib], Japanese encephalitis, Neisseria meningitidis serogroup A, measles, Streptococcu…”
BackgroundUnderstanding vaccine acceptance and demand—and ways to increase them
Habersaat, K. B., & Jackson, C. (2020) · Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz · doi:10.1007/s00103-019-03063-0 · Cited by 177 · cited 1×
“The Tailoring Immunization Programs [71] and Human Centered Design for Health [67] are tools to enable structured, adaptable and participatory processes to target undervaccinated or hesitant populations using behavioral insights to understand the barriers and enablers of vaccination and to design, implement, and evalu…”
MethodKrubiner, C. B., Faden, R. R., Karron, R. A., Little, M. O., Lyerly, A. D., Abramson, J. S., Beigi, R. H., Cravioto, A. R., Durbin, A. P., Gellin, B. G., et al. (2021) · Vaccine · doi:10.1016/j.vaccine.2019.01.011 · Cited by 169
Bloom, D. E. (2010) · Advances in experimental medicine and biology · doi:10.1007/978-1-4419-7185-2_1 · Cited by 158
Sim, S. Y., Watts, E., Constenla, D., Brenzel, L., & Patenaude, B. N. (2020) · Health Affairs · doi:10.1377/hlthaff.2020.00103 · Cited by 143
The expanded programme on immunization: A lasting legacy of smallpox eradication
Okwo‐Bele, J., & Cherian, T. (2011) · Vaccine · doi:10.1016/j.vaccine.2012.01.080 · Cited by 137 · cited 3×
“The global scaleup of immunization programs began with the establishment of EPI in 1974 by the World Health Assembly (WHA) [6].”
BackgroundSelf-citation(2009) · PubMed · Cited by 90
Addressing the persistent inequities in immunization coverage
Chopra, M., Bhutta, Z., Chang Blanc, D., Checchi, F., Gupta, A., Lemango, E. T., Levine, O. S., Lyimo, D., Nandy, R., O'Brien, K. L., et al. (2020) · Bulletin of the World Health Organization · doi:10.2471/blt.19.241620 · Cited by 90 · cited 1×
“They are disproportionately those who are impoverished, in rural areas and urban slums, or live in settings of conflict, fragility, or vulnerability [47].”
BackgroundSelf-citationLevels and Causes of Mortality under Age Five Years
Liu, L., Hill, K., Oza, S., Hogan, D. R., Chu, Y., Cousens, S., Mathers, C. D., Stanton, C., Lawn, J., & Black, R. E. (2016) · World Bank, Washington, DC eBooks · doi:10.1596/978-1-4648-0348-2_ch4 · Cited by 71 · cited 1×
“The World of Immunization • jid 2021:224 (Suppl 4) • S453 are fully or partially vaccine-preventable (ie, pneumonia, diarrhea, measles, and meningitis; Figure 2) [8].”
BackgroundProgress Toward Maternal and Neonatal Tetanus Elimination — Worldwide, 2000–2018
Njuguna, H. N., Yusuf, N., Raza, A. A., Ahmed, B., & Tohme, R. A. (2020) · MMWR Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm6917a2 · Cited by 70 · cited 2×
“By 2019, 47 (80%) of the 59 target countries had achieved elimination and the estimated number of neonatal tetanus deaths decreased by 85%, from about 171 000 in 2000 to 25 000 in 2018 [23].”
BackgroundReport on WHO meeting on immunization in older adults: Geneva, Switzerland, 22–23 March 2017
Aguado, M. T., Barratt, J., Beard, J., Blomberg, B. B., Chen, W. H., Hickling, J., Hyde, T. B., Jit, M., Jones, R., Poland, G. A., et al. (2018) · Vaccine · doi:10.1016/j.vaccine.2017.12.029 · Cited by 67 · cited 1×
“The reasons to build strong immunization services throughout the life course are many [84].”
BackgroundDerrough, T., Olsson, K., Gianfredi, V., Simondon, F., Heijbel, H., Danielsson, N., Kramarz, P., & Celentano, L. P. (2017) · Eurosurveillance · doi:10.2807/1560-7917.es.2017.22.17.30519 · Cited by 66
Kruk, M. E., Prescott, M. R., de Pinho, H., & Galea, S. (2009) · Human Resources for Health · doi:10.1186/1478-4491-7-27 · Cited by 56
New vaccine adoption in lower-middle-income countries
Makinen, M., Kaddar, M., Molldrem, V., & Wilson, L. (2012) · Health Policy and Planning · doi:10.1093/heapol/czs036 · Cited by 52 · cited 1×
“Previous studies have identified inefficient procurement as a barrier to competitive prices for vaccines [56].”
BackgroundGandhi, G., Lydon, P., Cornejo, S., Brenzel, L., Wrobel, S. J., & Chang, H. (2013) · Vaccine · doi:10.1016/j.vaccine.2013.01.036 · Cited by 48
Krubiner, C., & Faden, R. (2017) · Journal of Medical Ethics · doi:10.1136/medethics-2017-104446 · Cited by 48
Watts, E. A., Sim, S. Y., Constenla, D. O., Sriudomporn, S., Brenzel, L., & Patenaude, B. (2020) · Value in Health · doi:10.1016/j.jval.2020.07.009 · Cited by 45 · cited 1×
“2) in benefits [11], representing a return of $26.”
BackgroundHickler, B., MacDonald, N. E., Senouci, K., & Schuh, H. B. (2017) · Vaccine · doi:10.1016/j.vaccine.2017.04.056 · Cited by 39
Vaccine development and deployment: Opportunities and challenges in India
Gupta, S. S., Nair, G. B., Arora, N. K., & Ganguly, N. K. (2013) · Vaccine · doi:10.1016/j.vaccine.2012.11.079 · Cited by 37 · cited 1×
“LMIC manufacturers have an increasing role in vaccine supply, and their entrance into the market is stimulating price declines of key vaccines [35].”
BackgroundThe role of emerging manufacturers in access to innovative vaccines of public health importance
Milstien, J. B., & Kaddar, M. (2009) · Vaccine · doi:10.1016/j.vaccine.2009.12.036 · Cited by 36 · cited 1×
“More than 60% of the original 6 EPI vaccines are supplied by LMIC manufacturers [36], who are increasingly entering into development or technology transfer agreements with multinational manufacturers [37].”
BackgroundA call to action for the new decade of vaccines
Moxon, E. R., Das, P., Greenwood, B. M., Heymann, D. L., Horton, R. C., Levine, O. S., Plotkin, S. A., & Nossal, G. J. V. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60766-6 · Cited by 35 · cited 3×
“The authors gratefully acknowledge the contributions of the following staff from the Department of Immunization, Vaccines, and Biologicals and Global Polio Eradication Initiative, WHO, Geneva, and from the Immunization Departments at the WHO Regional Offices in providing information and data for preparing the manuscri…”
BackgroundHealth worker densities and immunization coverage in Turkey: a panel data analysis
Mitchell, A. D., Bossert, T. J., Yip, W., & Mollahaliloğlu, S. (2008) · Human Resources for Health · doi:10.1186/1478-4491-6-29 · Cited by 32
Immunization information system status in China, 2017
Wu, W., Cao, L., Zheng, J., Cao, L., Cui, J., & Xiao, Q.-Y. (2019) · Vaccine · doi:10.1016/j.vaccine.2019.08.070 · Cited by 30
Economic analyses of vaccine policies
Miller, M. A., & Hinman, A. R. (2013) · Elsevier eBooks · doi:10.1016/b978-1-4557-0090-5.00072-0 · Cited by 25
Assessing electronic immunization registries: the Pan American Health Organization experience
Danovaro-Holliday, M. C., Contreras, M. P., Pinto, D., Molina-Aguilera, I. B., Miranda, D., García, O., & Velandia-González, M. (2019) · Revista Panamericana de Salud Pública · doi:10.26633/rpsp.2019.28 · Cited by 24 · cited 1×
“Electronic immunization registries (EIRs) are computerized, confidential, populationbased systems that contain individual-level information on vaccine doses administered [59, 60].”
BackgroundPublic Health Workers and Vaccination Coverage in Eastern China: A Health Economic Analysis
Hu, Y., Shen, L., Guo, J., & Xie, S. (2014) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph110505555 · Cited by 19
WHO expectation and industry goals
Vandersmissen, W. (2001) · Vaccine · doi:10.1016/s0264-410x(00)00360-1 · Cited by 14
Key drivers behind the development of global vaccine market
Gréco, M. (2001) · Vaccine · doi:10.1016/s0264-410x(00)00359-5 · Cited by 14
Vaccines work: a reason for celebration and renewed commitment
Cohen, A. L., Patel, M. K., & Cherian, T. P. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00025-8 · Cited by 14 · cited 1×
“The total annual global deaths averted by vaccination go far beyond these estimates as only 98 countries were modeled, and deaths averted from polio, diphtheria, tetanus, pertussis, and from adult vaccinations were not modelled [10].”
BackgroundSelf-citationPagliusi, S. R., Makhoana, M., Datla, M., Leite, L., Hendriks, J., Gholami, A., Huang, W., Gao, Y., Jadhav, S. S., Harshavardhan, G. V. J. A., et al. (2013) · Vaccine · doi:10.1016/j.vaccine.2013.04.082 · Cited by 12 · cited 1×
“More than 60% of the original 6 EPI vaccines are supplied by LMIC manufacturers [36], who are increasingly entering into development or technology transfer agreements with multinational manufacturers [37].”
BackgroundIndustrial R&D paradigm shift to vaccines
Maggon, K. (2009) · Biotechnology Journal · doi:10.1002/biot.200900042 · Cited by 5
(1998) · PharmacoEconomics & Outcomes News · doi:10.1007/bf03277458 · Cited by 3
Caddell, A. M. (1999) · JAMA · doi:10.1001/jama.282.6.594-jbk0811-5-1 · Cited by 1
Cited by
Haeuser, E., Byrne, S., Nguyen, J., Raggi, C., McLaughlin, S. A., Bisignano, C., Harris, A. A., Smith, A. E., Lindstedt, P. A., Smith, G., et al. (2025) · The Lancet · doi:10.1016/s0140-6736(25)01037-2 · Cited by 143
“106 Proposed reductions in immunization spending are likely to disproportionally affect low-and middle-income countries, but high-income countries and territories are also likely to incur healthcare costs associated with new and more frequent disease outbreaks.”
Carter, A., Msemburi, W., Sim, S. Y., Gaythorpe, K. A. M., Lambach, P., Lindstrand, A., & Hutubessy, R. (2024) · Vaccine · doi:10.1016/j.vaccine.2023.07.033 · Cited by 121
Self-citationCoverage and Equity of Childhood Vaccines in China
Zhang, H., Lai, X., Mak, J., Sriudomporn, S., Zhang, H., Fang, H., & Patenaude, B. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2022.46005 · Cited by 79
Chen, S., Yao, L., Wang, W., & Tang, S. (2022) · The Lancet Public Health · doi:10.1016/s2468-2667(22)00171-2 · Cited by 61
In vitro immunity: an overview of immunocompetent organ-on-chip models
Morrison, A. I., Sjoerds, M. J., Vonk, L. A., Gibbs, S., & Koning, J. J. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1373186 · Cited by 61
“Signi fi cant improvements have been made, with key driving factors including vaccination programs, innovative research on disease pathophysiology, discovery of new drug targets and advancements in toxicity screenings (2, 3).”
Background
Metadata
- Authors
- Lindstrand, A., Cherian, T., Chang-Blanc, D., Feikin, D., & O’Brien, K. L.
- Affiliations
- World Health Organization (CH)
- MM Global Health Consulting, Geneva,Switzerland
- Immunization Vaccines and Biologicals Department, World Health Organization, Geneva, Switzerland
- Corresponding author
- O’Brien, Katherine L
- Venue
- The Journal of Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2021-09-30
- Volume
- 224
- Issue
- Supplement_4
- Pages
- S452-S467
- ISSN
- 0022-1899 (ISSN-L)
- 1537-6613
- PMC
- PMC8482029
- OpenAlex
- W3202596739
- Cited by
- 179
- References
- 40
- Citations by year
- 2026: 32 · 2025: 49 · 2024: 48 · 2023: 29 · 2022: 21
- FWCI
- 13.54
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- The Journal of Infectious Diseases (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, other-oa)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- Bill and Melinda Gates Foundation
- Topics
- Social Sciences › Health › Vaccine Coverage and Hesitancy
- Life Sciences › Immunology and Microbiology › Immunology › Immune responses and vaccinations
- Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Global Maternal and Child Health
- Keywords
- immunization, Expanded Programme on Immunization, Immunization Agenda 2030, vaccination coverage, vaccine inequity, vaccine-preventable diseases, vaccine access, global health strategy
- MeSH terms
- Vaccination Coverage, Vaccine-Preventable Diseases, Humans, Immunization, Vaccination, Vaccines, Immunization Programs
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.